Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29486521
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
Fardeau de la maladie chez les patients atteints de traitement Myasthénie réfractaire.
Engel-Nitz NM 1 , Boscoe A 2 , Wolbeck R 1 , Johnson J 1 , Silvestri NJ 3 .
Nerf musculaire. 2018 Feb 27. doi: 10.1002 / mus.26114.
This study assessed the clinical burden of refractory myasthenia gravis (MG), relative to non-refractory MG.
Rates of myasthenic crises, exacerbations, inpatient hospitalizations, and emergency room (ER) visits over a one-year period were measured for 403 refractory, 3,811 non-refractory, and 403 non-MG control patients from two administrative health plan databases.
Compared to non-refractory patients, a significantly greater percentage of refractory patients had at least one myasthenic crisis (21.3% versus 6.1%, p<0.001) and at least one exacerbation (71.2% versus 32.4%, p<0.001) over a one-year period. Refractory patients were also significantly more likely to be hospitalized and/or have an ER visit than non-refractory patients and non-MG controls (p<0.001 for all).
Refractory MG patients have significantly greater clinical burden and are more likely to utilize intensive healthcare resources than non-refractory patients. Furthermore, refractory patients may be at greater risk of crises throughout the disease course than previous studies have suggested.